Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14501858 | 1.00 | CHRM2 (0.35) | CHRM2CHRM1CHRM3ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL5376255 | 0.98 | CHRM2 (0.34) | CHRM2CHRM1CHRM3ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL5376252 | 0.98 | CHRM2 (0.34) | CHRM2CHRM1CHRM3ALDH1A1LMNA | |
| SCHEMBL14033833 | 0.75 | CHRM2 (0.33) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL10537423 | 0.74 | CHRM2 (0.34) | CHRM2CHRM1CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10537417 | 0.72 | ALDH1A1 (0.34) | CHRM2CHRM1CHRM3ALDH1A1 | |
| Hydrochloric Acid SCHEMBL10537410 | 0.72 | ALDH1A1 (0.34) | CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL14033267 | 0.72 | CHRM1 (0.39) | CHRM2CHRM1CHRM3ALDH1A1SMN1; SMN2 | |
| SCHEMBL7818550 | 0.71 | — | — | |
| SCHEMBL14490824 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-20070135641-A1 | Synthesis | PALMER RICHARD M J | 2007-06-14 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-7189852-B2 | Preparing renzapride (hydrochloride) on a laboratory or industrial scale by a simplified process of forming the acyl chloride derivative of 2-(methoxy),3-acyamino,5-chlorobenzoic acid by reacting oxalyl or thionyl chloride in a solvent, e.g. dimethylformamide; coupling with 1-diazabicylo(3.3.1)nonane | ALIZYME THERAPEUTICS LIMITED (GB) | 2007-03-13 | — | — | US | disclosed |
| US-20050049416-A1 | Synthesis | ENDOLOGIC LLC | 2005-03-03 | — | — | US | disclosed |
| EP-0094742-B1 | SUBSTITUTED AZABICYCLO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | BEECHAM GROUP PLC (GB) | 1990-08-01 | — | — | EP | disclosed |
| US-4857647-A | 4-amino-5-chloro-2-methoxy-n-(6-(1-azabicyclo[3,2,1]octyl)benzamide | BEECHAM GROUP P.L.C. (GB) | 1989-08-15 | — | — | US | disclosed |
| US-4697019-A | Azabicyclo compounds, useful as intermediates | BEECHAM GROUP P.L.C. (GB) | 1987-09-29 | — | — | US | disclosed |
| US-4612319-A | Bridged quinolizidinylbenzamides, compositions containing them and methods for their use | BEECHAM GROUP P.L.C. (GB) | 1986-09-16 | — | — | US | disclosed |
| EP-0094742-A2 | Substituted azabicyclo compounds, process for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049416-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | CHRM2 3747/4885CHRM1 3005/4885CHRM3 3438/4885 |
| US-20070135641-A1 | Synthesis | ALKBH5, AZI2, ALKBH1 | CHRM2 3747/4885CHRM1 3005/4885CHRM3 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.